<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:40:20Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6502682" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6502682</identifier>
        <datestamp>2019-06-20</datestamp>
        <setSpec>blackwellopen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Alcohol Clin Exp Res</journal-id>
              <journal-id journal-id-type="iso-abbrev">Alcohol. Clin. Exp. Res</journal-id>
              <journal-id journal-id-type="doi">10.1111/(ISSN)1530-0277</journal-id>
              <journal-id journal-id-type="publisher-id">ACER</journal-id>
              <journal-title-group>
                <journal-title>Alcoholism, Clinical and Experimental Research</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0145-6008</issn>
              <issn pub-type="epub">1530-0277</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6502682</article-id>
              <article-id pub-id-type="pmcid">PMC6502682</article-id>
              <article-id pub-id-type="pmc-uid">6502682</article-id>
              <article-id pub-id-type="pmid">30951210</article-id>
              <article-id pub-id-type="doi">10.1111/acer.14018</article-id>
              <article-id pub-id-type="publisher-id">ACER14018</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Original Article</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Behavior, Treatment and Prevention</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Maintenance of World Health Organization Risk Drinking Level Reductions and Posttreatment Functioning Following a Large Alcohol Use Disorder Clinical Trial</article-title>
                <alt-title alt-title-type="left-running-head">Witkiewitz et al.</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="acer14018-cr-0001" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Witkiewitz</surname>
                    <given-names>Katie</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1086-3067</contrib-id>
                  <address>
                    <email>katiew@unm.edu</email>
                  </address>
                  <xref ref-type="aff" rid="acer14018-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="acer14018-cr-0002" contrib-type="author">
                  <name>
                    <surname>Falk</surname>
                    <given-names>Daniel E.</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3753-2786</contrib-id>
                  <xref ref-type="aff" rid="acer14018-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="acer14018-cr-0003" contrib-type="author">
                  <name>
                    <surname>Litten</surname>
                    <given-names>Raye Z.</given-names>
                  </name>
                  <xref ref-type="aff" rid="acer14018-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="acer14018-cr-0004" contrib-type="author">
                  <name>
                    <surname>Hasin</surname>
                    <given-names>Deborah S.</given-names>
                  </name>
                  <xref ref-type="aff" rid="acer14018-aff-0003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="acer14018-cr-0005" contrib-type="author">
                  <name>
                    <surname>Kranzler</surname>
                    <given-names>Henry R.</given-names>
                  </name>
                  <xref ref-type="aff" rid="acer14018-aff-0004">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="acer14018-cr-0006" contrib-type="author">
                  <name>
                    <surname>Mann</surname>
                    <given-names>Karl F.</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2087-1976</contrib-id>
                  <xref ref-type="aff" rid="acer14018-aff-0005">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="acer14018-cr-0007" contrib-type="author">
                  <name>
                    <surname>O'Malley</surname>
                    <given-names>Stephanie S.</given-names>
                  </name>
                  <xref ref-type="aff" rid="acer14018-aff-0006">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib id="acer14018-cr-0008" contrib-type="author">
                  <name>
                    <surname>Anton</surname>
                    <given-names>Raymond F.</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3417-6576</contrib-id>
                  <xref ref-type="aff" rid="acer14018-aff-0007">
                    <sup>7</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="acer14018-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">Department of Psychology</named-content>
                <institution>University of New Mexico</institution>
                <named-content content-type="city">Albuquerque</named-content>
                <named-content content-type="country-part">New Mexico</named-content>
              </aff>
              <aff id="acer14018-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <institution>National Institute on Alcohol Abuse and Alcoholism</institution>
                <named-content content-type="city">Bethesda</named-content>
                <named-content content-type="country-part">Maryland</named-content>
              </aff>
              <aff id="acer14018-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">Department of Epidemiology</named-content>
                <institution>Columbia University</institution>
                <named-content content-type="city">New York</named-content>
                <named-content content-type="country-part">New York</named-content>
              </aff>
              <aff id="acer14018-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <named-content content-type="organisation-division">Department of Psychiatry</named-content>
                <institution>University of Pennsylvania</institution>
                <named-content content-type="city">Philadelphia</named-content>
                <named-content content-type="country-part">Pennsylvania</named-content>
              </aff>
              <aff id="acer14018-aff-0005">
                <label>
                  <sup>5</sup>
                </label>
                <named-content content-type="organisation-division">Medical Faculty Mannheim</named-content>
                <named-content content-type="organisation-division">Central Institute of Mental Health</named-content>
                <institution>Heidelberg University</institution>
                <named-content content-type="city">Mannheim</named-content>
                <country country="DE">Germany</country>
              </aff>
              <aff id="acer14018-aff-0006">
                <label>
                  <sup>6</sup>
                </label>
                <institution>Yale School of Medicine</institution>
                <named-content content-type="city">New Haven</named-content>
                <named-content content-type="country-part">Connecticut</named-content>
              </aff>
              <aff id="acer14018-aff-0007">
                <label>
                  <sup>7</sup>
                </label>
                <named-content content-type="organisation-division">Department of Psychiatry and Behavioral Sciences</named-content>
                <institution>Medical University of South Carolina</institution>
                <named-content content-type="city">Charleston</named-content>
                <country>South Carolina</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label>Reprint requests: Katie Witkiewitz, PhD, Department of Psychology, University of New Mexico, MSC 03‐2220, Albuquerque, NM 87131; Tel.: 505‐925‐2334; Fax: 505‐277‐1394; E‐mail: <email>katiew@unm.edu</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>05</day>
                <month>4</month>
                <year>2019</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>5</month>
                <year>2019</year>
              </pub-date>
              <volume>43</volume>
              <issue>5</issue>
              <issue-id pub-id-type="doi">10.1111/acer.2019.43.issue-5</issue-id>
              <fpage>979</fpage>
              <lpage>987</lpage>
              <history>
                <date date-type="received">
                  <day>20</day>
                  <month>1</month>
                  <year>2019</year>
                </date>
                <date date-type="accepted">
                  <day>02</day>
                  <month>3</month>
                  <year>2019</year>
                </date>
              </history>
              <permissions>
                <!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2019 Research Society on Alcoholism <copyright-statement>-->
                <copyright-statement content-type="article-copyright">© 2019 The Authors. Alcoholism: Clinical &amp; Experimental Research published by Wiley Periodicals, Inc. on behalf of Research Society on Alcoholism</copyright-statement>
                <license license-type="creativeCommonsBy-nc-nd">
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:type="simple" xlink:href="file:ACER-43-979.pdf"/>
              <abstract id="acer14018-abs-0001">
                <sec id="acer14018-sec-0001">
                  <title>Background</title>
                  <p>Reductions in the World Health Organization (WHO) risk drinking levels have been proposed as an alternative primary outcome for alcohol clinical trials. Yet, little is known about whether reductions in WHO risk drinking levels can be maintained over time. The current study examined whether reductions in WHO risk drinking levels were maintained for up to 1 year following treatment, and whether reductions over time were associated with improvements in functioning.</p>
                </sec>
                <sec id="acer14018-sec-0002">
                  <title>Methods</title>
                  <p>Secondary data analysis of individuals with alcohol dependence (<italic>n</italic> = 1,226) enrolled in the COMBINE study, a multisite, randomized, placebo‐controlled clinical trial. Logistic regression was used to examine the maintenance of end‐of‐treatment WHO risk level reductions and WHO risk level reductions at the 1‐year follow‐up. Repeated‐measures mixed models were used to examine the association between WHO risk level reductions and functional outcomes over time.</p>
                </sec>
                <sec id="acer14018-sec-0003">
                  <title>Results</title>
                  <p>Achieving at least a 1‐ or 2‐level reduction in risk by the end of treatment was significantly associated with WHO risk level reductions at the 1‐year follow‐up assessment (<italic>p &lt; </italic>0.001). Among individuals who achieved at least a 1‐level reduction by the end of treatment, 85.5% reported at least a 1‐level reduction at the 1‐year follow‐up. Among individuals who achieved at least a 2‐level reduction by the end of treatment, 77.8% reported at least a 2‐level reduction at the 1‐year follow‐up. WHO risk level reductions were associated with significantly lower alcohol consumption, better physical health (<italic>p </italic>&lt;<italic> </italic>0.01), and fewer alcohol‐related consequences (<italic>p &lt; </italic>0.001) up to 1 year following treatment.</p>
                </sec>
                <sec id="acer14018-sec-0004">
                  <title>Conclusions</title>
                  <p>One‐ and 2‐level reductions in WHO risk levels during alcohol treatment were maintained after treatment and associated with better functioning over time. These findings support the use of the WHO risk level reductions as an outcome measure that reflects clinically significant improvement in how individuals seeking treatment for alcohol use disorder feel and function.</p>
                </sec>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="acer14018-kwd-0001">World Health Organization Risk Drinking Levels</kwd>
                <kwd id="acer14018-kwd-0002">Alcohol Use Disorder</kwd>
                <kwd id="acer14018-kwd-0003">Reduced Alcohol Consumption</kwd>
                <kwd id="acer14018-kwd-0004">Alcohol Treatment Outcomes</kwd>
                <kwd id="acer14018-kwd-0005">Low‐Risk Drinking</kwd>
                <kwd id="acer14018-kwd-0006">Alcohol Dependence</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>National Institute on Alcohol Abuse and Alcoholism</funding-source>
                  <award-id>R01AA022328</award-id>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="2"/>
                <table-count count="3"/>
                <page-count count="9"/>
                <word-count count="7272"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>component-id</meta-name>
                  <meta-value>acer14018</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>May 2019</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.6.4 mode:remove_FC converted:13.06.2019</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <p>For individuals treated for alcohol use disorder (AUD), engaging in some level of drinking following treatment is common (Hunt et al., <xref rid="acer14018-bib-0015" ref-type="ref">1971</xref>; Maisto et al., <xref rid="acer14018-bib-0021" ref-type="ref">2018</xref>; Witkiewitz and Masyn, <xref rid="acer14018-bib-0038" ref-type="ref">2008</xref>). Sustained abstinence has long been considered the optimal outcome of AUD treatment (Betty Ford Institute Consensus Panel, <xref rid="acer14018-bib-0005" ref-type="ref">2007</xref>; Mann et al., <xref rid="acer14018-bib-0023" ref-type="ref">2017</xref>), and most research historically focused on abstinence as a primary measure of treatment outcomes (e.g., percent days abstinent from alcohol; Anton et al., <xref rid="acer14018-bib-0003" ref-type="ref">2006</xref>; Maisto et al., <xref rid="acer14018-bib-0022" ref-type="ref">2016</xref>). Yet, individuals seeking treatment for AUD are increasingly interested in drinking reduction goals (DeMartini et al., <xref rid="acer14018-bib-0007" ref-type="ref">2014</xref>; Haug et al., <xref rid="acer14018-bib-0014" ref-type="ref">2018</xref>; Ryan et al., <xref rid="acer14018-bib-0031" ref-type="ref">2017</xref>) and AUD treatment professionals have become more accepting of patients' drinking reduction goals (Davis and Rosenberg, <xref rid="acer14018-bib-0006" ref-type="ref">2013</xref>; Rosenberg and Davis, <xref rid="acer14018-bib-0030" ref-type="ref">1994</xref>). Given a growing interest in drinking reduction as a goal of AUD treatment (van Amsterdam and van den Brink, <xref rid="acer14018-bib-0034" ref-type="ref">2013</xref>; Mann et al., <xref rid="acer14018-bib-0023" ref-type="ref">2017</xref>), examining whether drinking reductions are maintained over time and associated with improvements in patients' functioning is an important question for AUD treatment outcomes research.</p>
            <sec disp-level="2" id="acer14018-sec-0006">
              <title>Primary Measures of AUD Treatment Outcomes</title>
              <p>The Food and Drug Administration's (FDA's) draft guidance on the development of alcohol treatment medications (Food and Drug Administration, <xref rid="acer14018-bib-0010" ref-type="ref">2015</xref>) recommended 2 potential AUD treatment outcomes (i.e., end points) for medication development: (i) sustained abstinence; or (ii) no heavy drinking days, with heavy drinking days defined as more than 3 drinks in a day for women and 4 drinks in a day for men (National Institute on Alcohol Abuse and Alcoholism, <xref rid="acer14018-bib-0027" ref-type="ref">2005</xref>). The European Medicines Agency (EMA, <xref rid="acer14018-bib-0008" ref-type="ref">2010</xref>) recommends abstinence as a primary end point, but acknowledges the utility of drinking reduction end points for alcohol clinical trials, including reductions in total alcohol consumption, in heavy drinking days, or in the World Health Organization (WHO) risk drinking levels (WHO, <xref rid="acer14018-bib-0040" ref-type="ref">2000</xref>), which are defined by sex‐specific limits on the number of grams (g) of alcohol consumed per day. Specifically, as shown in Fig. <xref rid="acer14018-fig-0001" ref-type="fig">1</xref>, individuals can be abstinent (0 g males/females), low risk (1 to 40 g males/1 to 20 g females), medium risk (41 to 60 g males/21 to 40 g females), high risk (61 to 100 g males/41 to 60 g females), or very high risk (101+ g males/61+ g females). Importantly, guidance from both the FDA and the EMA highlights that end points for alcohol clinical trials should be associated with improvements in patient functioning.</p>
              <fig fig-type="Figure" xml:lang="en" id="acer14018-fig-0001" orientation="portrait" position="float">
                <label>Figure 1</label>
                <caption>
                  <p>WHO risk drinking level (grams [g] of pure alcohol per day for males/females) by months from baseline, during treatment (months 1 to 4), and at each follow‐up month (months 5 to 16).</p>
                </caption>
                <graphic id="nlm-graphic-3" xlink:href="ACER-43-979-g001"/>
              </fig>
              <p>Reduction in the WHO risk levels as a potential outcome measure has recently been studied in both populations of individuals receiving treatment for AUD (Aubin et al., <xref rid="acer14018-bib-0004" ref-type="ref">2015</xref>; O'Malley et al., <xref rid="acer14018-bib-0028" ref-type="ref">2018</xref>; Witkiewitz et al., <xref rid="acer14018-bib-0036" ref-type="ref">2017a</xref>, <xref rid="acer14018-bib-0037" ref-type="ref">2018</xref>) and a general population sample of alcohol drinkers (Hasin et al., <xref rid="acer14018-bib-0013" ref-type="ref">2017</xref>; Knox et al., <xref rid="acer14018-bib-0018" ref-type="ref">2018</xref>). Findings across studies show that reductions in WHO risk drinking levels are associated with significant differences between active medication treatments and placebo (Aubin et al., <xref rid="acer14018-bib-0004" ref-type="ref">2015</xref>; Falk et al., <xref rid="acer14018-bib-0009" ref-type="ref">2019</xref>; O'Malley et al., <xref rid="acer14018-bib-0028" ref-type="ref">2018</xref>), improvements in physical health and the quality of life (Knox et al., <xref rid="acer14018-bib-0018" ref-type="ref">2018</xref>, <xref rid="acer14018-bib-0017" ref-type="ref">2019</xref>; Witkiewitz et al., <xref rid="acer14018-bib-0037" ref-type="ref">2018</xref>), reduced risk of alcohol dependence (Hasin et al., <xref rid="acer14018-bib-0013" ref-type="ref">2017</xref>), and reductions in drinking‐related consequences and improvements in mental health (Witkiewitz et al., <xref rid="acer14018-bib-0036" ref-type="ref">2017a</xref>).</p>
            </sec>
            <sec disp-level="2" id="acer14018-sec-0007">
              <title>Current Study: Examining the Maintenance of Drinking Reduction Outcomes</title>
              <p>A major concern with nonabstinent drinking reduction outcomes is that they may not be maintained over time (Anton et al., <xref rid="acer14018-bib-0002" ref-type="ref">2012</xref>). For example, the FDA recommends that clinical trials be 6 months in duration based on the notion that “drinking patterns over shorter durations of time, such as 12 weeks, may not be stable or representative of future experience” (FDA, <xref rid="acer14018-bib-0010" ref-type="ref">2015</xref>, p. 5). Recent work in the field has supported the maintenance of low‐risk drinking outcomes, defined as not exceeding heavy drinking limits, over 1 year (Witkiewitz et al., <xref rid="acer14018-bib-0039" ref-type="ref">2017b</xref>), 3 years (Maisto et al., <xref rid="acer14018-bib-0020" ref-type="ref">2007</xref>), and up to 9 years following treatment (Kline‐Simon et al., <xref rid="acer14018-bib-0016" ref-type="ref">2017</xref>). However, the maintenance of the WHO risk drinking level reductions has not been studied extensively. Aubin and colleagues (<xref rid="acer14018-bib-0004" ref-type="ref">2015</xref>) examined whether individuals who received nalmefene, compared to placebo, had a higher likelihood of achieving a 2‐level reduction in WHO risk drinking level over a 6‐month clinical trial, but did not examine the maintenance of the 2‐level reduction outcome beyond 6 months. Witkiewitz and colleagues (<xref rid="acer14018-bib-0036" ref-type="ref">2017a</xref>, <xref rid="acer14018-bib-0037" ref-type="ref">2018</xref>) examined whether reductions in WHO risk levels during a 4‐month clinical trial, the COMBINE study, predicted functioning for up to 1 year following treatment, but did not examine whether reductions in WHO risk drinking levels themselves were maintained beyond the 4‐month trial period. To address this gap in the literature, the current study examined the maintenance of the WHO risk level reductions for up to 1 year following treatment. In line with FDA and EMA guidance, we also tested whether WHO risk level reductions were associated with functional improvement. We hypothesized that 1‐ and 2‐level reductions in WHO risk levels would be maintained over time and that reductions in WHO risk levels would be associated with better functional outcomes over time.</p>
            </sec>
            <sec id="acer14018-sec-0008">
              <title>Materials and Methods</title>
              <sec id="acer14018-sec-0009">
                <title>Participants and Procedures</title>
                <p>The data for the current study were from the COMBINE study (Anton et al., <xref rid="acer14018-bib-0003" ref-type="ref">2006</xref>), a U.S. multisite, randomized, double‐blind, placebo‐controlled clinical trial that examined combinations of medications and behavioral interventions for treating alcohol dependence. All participants met the criteria for alcohol dependence based on DSM‐IV (American Psychiatric Association, <xref rid="acer14018-bib-0001" ref-type="ref">1994</xref>) and had at least 2 heavy drinking days (defined as more than 3 drinks for women and more than 4 drinks for men) in a consecutive 30‐day period within the 90 days prior to the baseline assessment. Exclusion criteria were a current substance use disorder (other than nicotine or cannabis), a psychiatric disorder requiring medication, or unstable medical conditions. Participants in the current analyses (<italic>n</italic> = 1,226) were randomized to receive: (i) active naltrexone (100 mg/d) or placebo naltrexone; (ii) active acamprosate (3,000 mg/d) or placebo acamprosate; or (iii) medication management (MM) or combined behavioral intervention with MM.</p>
                <p>Follow‐up assessments were completed at the end of treatment (16 weeks after baseline) and at 3 assessments after treatment: 10 weeks posttreatment (26 weeks after baseline), 36 weeks posttreatment (52 weeks after baseline), and 1 year posttreatment (68 weeks after baseline).</p>
              </sec>
              <sec id="acer14018-sec-0010">
                <title>Measures</title>
                <sec id="acer14018-sec-0011">
                  <title>Demographics</title>
                  <p>Demographics, including age, sex, and race/ethnicity, were assessed using a self‐report demographic questionnaire.</p>
                </sec>
                <sec id="acer14018-sec-0012">
                  <title>Alcohol Consumption</title>
                  <p>Daily standard drinks were measured using the Form‐90 (Miller, <xref rid="acer14018-bib-0024" ref-type="ref">1996</xref>) and Timeline Follow‐Back interview (Sobell and Sobell, <xref rid="acer14018-bib-0032" ref-type="ref">1992</xref>). We calculated WHO risk drinking levels based on the number of standard drinks (defined as 0.6 ounces of absolute alcohol = 14 g of pure alcohol). WHO risk levels were calculated based on the average number of grams of alcohol consumed per day (i.e., drinks per day) over a specific time period (in the current study, we averaged over 1‐month time periods). For the baseline period, we calculated the WHO risk drinking level using data from the month prior to the screening.</p>
                  <p>For all analyses, binary variables were included that reflected at least 1‐ or 2‐level reductions in the WHO risk drinking levels from baseline to each month of treatment (postbaseline months 1 through 4) and from baseline to each follow‐up month (postbaseline months 5 through 16). The reference group for the 1‐level reduction was no change or an increase in the WHO risk drinking level from baseline to the treatment/follow‐up months, and the reference group for the 2‐level reduction was the 1‐level reduction, no change, or increase in the WHO risk level from baseline to the treatment/follow‐up months.</p>
                  <p>Data from the Form‐90 (Miller, <xref rid="acer14018-bib-0024" ref-type="ref">1996</xref>) and Timeline Follow‐Back interview (Sobell and Sobell, <xref rid="acer14018-bib-0032" ref-type="ref">1992</xref>) were also used to calculate the alcohol consumption outcomes—percent heavy drinking days, percent drinking days, and drinks per drinking day—at the end of treatment (postbaseline week 16), 10 weeks posttreatment (post‐baseline week 26), 36 weeks posttreatment (postbaseline week 52), and 1 year posttreatment (postbaseline week 68).</p>
                </sec>
                <sec id="acer14018-sec-0013">
                  <title>Functioning Outcomes</title>
                  <p>Biological functioning was assessed at end of treatment (postbaseline week 16), 10 weeks posttreatment (postbaseline week 26), and 36 weeks posttreatment (postbaseline week 52), and included systolic blood pressure (SBP) and levels of the liver enzymes aspartate aminotransferase (AST), alanine aminotransferase (ALT), and γ‐glutamyltransferase (GGT). SBP was assessed at each clinic visit by clinical staff, and blood samples were sent to a central laboratory (Quintiles Laboratories, Marietta, GA) in which AST, ALT, and GGT clinical assays were performed utilizing automatic analyzer procedures. Lower levels of SBP, AST, ALT, and GGT are associated with better health outcomes (Kwo et al., <xref rid="acer14018-bib-0019" ref-type="ref">2017</xref>; Strandberg and Pitkala, <xref rid="acer14018-bib-0033" ref-type="ref">2003</xref>).</p>
                  <p>Alcohol‐related consequences were assessed with the Drinker Inventory of Consequences (DrInC; Miller et al., <xref rid="acer14018-bib-0025" ref-type="ref">1995</xref>), a 50‐item measure that uses a 4‐level response scale (0 = never and 3 = daily or almost daily). The DrInC total score (based on 45 drinking consequences, excluding the 5 control items) was used to assess alcohol‐related consequences at the 1‐year follow‐up (Cronbach's <italic>α</italic> = 0.97).</p>
                </sec>
              </sec>
              <sec id="acer14018-sec-0014">
                <title>Statistical Analysis</title>
                <p>Descriptive and inferential analyses were used to examine the maintenance of risk level reductions over time. Descriptive frequencies were used to determine the observed monthly prevalence of risk drinking level reductions. For inferential analyses, we used logistic regression and repeated‐measures mixed models to examine associations between WHO risk level reductions and functioning outcomes up to 1 year posttreatment. First, we examined the association between risk level reductions achieved in the last month of treatment and at 1 year posttreatment using logistic regression. Specifically, these analyses examined the odds of maintaining 1‐ and 2‐level reductions at the 1‐year follow‐up assessment as a function of achieving 1‐ and 2‐level reductions at the end of treatment, respectively. Second, to examine associations across all follow‐up months, general linear repeated‐measures mixed models with an identity link function were used to assess the association between WHO risk level reductions in each month over time and functional outcomes at each assessment over time. All mixed models were estimated using M<italic>plus</italic> version 8 (Muthén and Muthén, <xref rid="acer14018-bib-0026" ref-type="ref">1998</xref>) using maximum likelihood estimation with robust estimation of standard errors to account for clustering within treatment sites (Yuan and Bentler, <xref rid="acer14018-bib-0041" ref-type="ref">2010</xref>). Missing data were accommodated via maximum likelihood estimation procedures, which provide an estimate of the variance–covariance matrix given all available data and allow for some missing data across months (Hallgren and Witkiewitz, <xref rid="acer14018-bib-0011" ref-type="ref">2013</xref>; Witkiewitz et al., <xref rid="acer14018-bib-0035" ref-type="ref">2014</xref>). Consistent with prior analyses examining the WHO risk level reductions in the COMBINE study data (Witkiewitz et al., <xref rid="acer14018-bib-0036" ref-type="ref">2017a</xref>, <xref rid="acer14018-bib-0037" ref-type="ref">2018</xref>), we controlled for the following covariates in all analyses: age, sex, body mass index, smoking status, and baseline WHO risk level. All covariates were grand‐mean centered.</p>
                <sec id="acer14018-sec-0015">
                  <title>Sensitivity Analyses</title>
                  <p>For all analyses, we performed 2 sets of sensitivity analyses. First, we reestimated all models with no change/increase imputed for individuals with missing drinking data, which was a small percent of the sample in each month (range of 1% in month 1 to 20% in month 16) given excellent retention in the COMBINE study (Anton et al., <xref rid="acer14018-bib-0003" ref-type="ref">2006</xref>). This method of imputing “failure” for missing outcomes has been shown to produce biased estimates (Hallgren et al., <xref rid="acer14018-bib-0012" ref-type="ref">2016</xref>); however, it is commonly recommended as a sensitivity analysis by regulatory agencies, including the FDA. Second, we examined the effect of excluding abstainers by conducting analyses among individuals who achieved 1‐ and 2‐level reductions and were not abstinent. These analyses provided a test of whether reductions in drinking, short of abstinence, were associated with maintenance of risk level reductions (short of abstinence) and improvements in functioning over time.</p>
                </sec>
              </sec>
            </sec>
            <sec id="acer14018-sec-0016">
              <title>Results</title>
              <sec id="acer14018-sec-0017">
                <title>Descriptive Analyses</title>
                <p>Participants were mostly male (68.8%) and non‐Hispanic white (76.7%) (black/African American [7.9%], Asian [0.3%], Hispanic (11.2%), American Indian/Alaska Native [1.3%)], multiracial [1.3%], and other race [1.2%]), with an average age of 44.4 years (SD<italic> </italic>=<italic> </italic>10.2). At baseline, the majority of individuals (69.1%) were in the “very high risk” category (drinking over 101/61 [males/females] grams of pure alcohol per day on average) and there were no abstainers. As shown in Fig. <xref rid="acer14018-fig-0001" ref-type="fig">1</xref>, more than half of the sample was categorized as abstinent or low risk in every month following baseline (note that 1 person was missing drinking data at baseline for a baseline sample size of <italic>n</italic> = 1,225).</p>
                <p>The binary WHO risk level reduction variables were then created by calculating the reduction in risk drinking level from baseline to each month of treatment (months 1 to 4) and up to 12 months posttreatment (months 5 to 16). The majority of the sample reduced their drinking from baseline to the last month of treatment (month 4) by at least 1 level (<italic>n</italic> = 1,011, 88.5%) or at least 2 levels (<italic>n</italic> = 881, 77.1%). The percentage of individuals who achieved at least 1‐ and at least 2‐level reductions ranged from 79.0 to 84.2% and from 63.8 to 70.4%, respectively, across the follow‐up months (see Fig. <xref rid="acer14018-fig-0002" ref-type="fig">2</xref>).</p>
                <fig fig-type="Figure" xml:lang="en" id="acer14018-fig-0002" orientation="portrait" position="float">
                  <label>Figure 2</label>
                  <caption>
                    <p>Percentage of participants achieving WHO risk level reductions from baseline to each month of treatment (months 1 to 4) and posttreatment (months 5 to 16).</p>
                  </caption>
                  <graphic id="nlm-graphic-5" xlink:href="ACER-43-979-g002"/>
                </fig>
              </sec>
              <sec id="acer14018-sec-0018">
                <title>Logistic Regression</title>
                <p>Results from the logistic regression models indicated that reduction in WHO risk levels in the last month of treatment was significantly associated with at least 1‐ and 2‐level reductions in WHO risk levels at 1 year following treatment. Achieving at least a 1‐ or 2‐level reduction during the last month of treatment was associated with 9 to 10 times the odds of reporting at least a 1‐ or 2‐level reduction, respectively, at 1 year following treatment (1‐level reduction: Nagelkerke <italic>R</italic>
<sup>2</sup> = 0.20; <italic>B</italic>[SE] = 2.33 [0.24], <italic>p </italic>&lt;<italic> </italic>0.001; odds ratio [OR] [95% confidence interval (CI)] = 10.25 [6.44, 16.29]; 2‐level reduction: Nagelkerke <italic>R</italic>
<sup>2</sup> = 0.27; <italic>B</italic>[SE] = 2.24 [0.20], <italic>p </italic>&lt;<italic> </italic>0.001; OR [95% confidence interval (CI)] = 9.40 [6.42, 13.78]). Among individuals who achieved at least a 1‐level reduction by the end of treatment, 85.5% reported at least a 1‐level reduction at the 1‐year follow‐up. Similarly, among individuals who achieved a least a 2‐level reduction by the end of treatment, 77.8% reported at least a 2‐level reduction at the 1‐year follow‐up.</p>
              </sec>
              <sec id="acer14018-sec-0019">
                <title>Linear Mixed Models</title>
                <p>Next, we examined whether 1‐ and 2‐level reductions in WHO risk levels over time were associated with physical health, drinking consequences, and other measures of alcohol consumption over time. Descriptive statistics for functional outcomes by 1‐ and 2‐level reduction groups are provided in Table <xref rid="acer14018-tbl-0001" ref-type="table">1</xref> (physical health outcomes) and Table <xref rid="acer14018-tbl-0002" ref-type="table">2</xref> (drinking outcomes). Results from the linear mixed models are provided in Table <xref rid="acer14018-tbl-0003" ref-type="table">3</xref>. The reference group for the 1‐level reduction showed no change or an increase in the WHO risk drinking level, and the reference group for the 2‐level reduction showed a 1‐level reduction, no change, or an increase in the WHO risk level from baseline to the treatment/follow‐up months. Unstandardized coefficients can be interpreted as the decrease in outcomes over time based on achieving at least a 1‐ and 2‐level reduction over time, at the average level of covariates (covariate effects shown in Table <xref rid="acer14018-sup-0001" ref-type="supplementary-material">S1</xref>). For example, at least a 1‐level reduction over time was associated with a 6.42 mm Hg reduction in SBP (<italic>p </italic>&lt;<italic> </italic>0.001), a 7.87 IU/l reduction in AST (<italic>p </italic>&lt;<italic> </italic>0.001), a 6.33 IU/l reduction in ALT (<italic>p </italic>&lt;<italic> </italic>0.001), a 26.92 IU/l reduction in GGT (<italic>p </italic>=<italic> </italic>0.01), a reduction of 19.24 in DrInC total score (<italic>p </italic>&lt;<italic> </italic>0.001), and lower drinking intensity and drinking frequency over time (all <italic>p </italic>&lt;<italic> </italic>0.001). These findings reflect better functioning, on average over time, than in individuals with no change or an increase in the WHO risk drinking level over time. At least a 2‐level reduction was associated with a 6.00 mm Hg reduction in SBP (<italic>p </italic>&lt;<italic> </italic>0.001), a 7.19 IU/l reduction in AST (<italic>p </italic>&lt;<italic> </italic>0.001), a 6.00 IU/l reduction in ALT (<italic>p </italic>&lt;<italic> </italic>0.001), a 21.84 IU/l reduction in GGT (<italic>p </italic>=<italic> </italic>0.005), a reduction of 17.40 in DrInC total score (<italic>p </italic>&lt;<italic> </italic>0.001), and lower drinking intensity and frequency (all <italic>p </italic>&lt;<italic> </italic>0.001) than in individuals with a 1‐level reduction, no change, or an increase in the WHO risk drinking level over time.</p>
                <table-wrap id="acer14018-tbl-0001" xml:lang="en" orientation="portrait" position="float">
                  <label>Table 1</label>
                  <caption>
                    <p>Means (Standard Deviations [SDs]) for Each Physical Health Outcome by at Least 1‐ and 2‐Level Reductions at Each Assessment Time Point</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1">Outcome</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">No change or increase mean (SD)</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">At least 1‐level reduction mean (SD)</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">1‐level reduction, no change, or increase mean (SD)</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">At least 2‐level reduction mean (SD)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">SBP (mm/Hg)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Week 16</td>
                        <td align="char" char="." rowspan="1" colspan="1">137.9 (17.6)</td>
                        <td align="char" char="." rowspan="1" colspan="1">129.8 (16.6)</td>
                        <td align="char" char="." rowspan="1" colspan="1">134.2 (17.1)</td>
                        <td align="char" char="." rowspan="1" colspan="1">129.5 (16.6)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Week 26</td>
                        <td align="char" char="." rowspan="1" colspan="1">138.6 (17.5)</td>
                        <td align="char" char="." rowspan="1" colspan="1">130.3 (17.9)</td>
                        <td align="char" char="." rowspan="1" colspan="1">135.5 (19.2)</td>
                        <td align="char" char="." rowspan="1" colspan="1">129.9 (17.3)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Week 52</td>
                        <td align="char" char="." rowspan="1" colspan="1">136.7 (16.9)</td>
                        <td align="char" char="." rowspan="1" colspan="1">130.6 (17.2)</td>
                        <td align="char" char="." rowspan="1" colspan="1">134.4 (17.7)</td>
                        <td align="char" char="." rowspan="1" colspan="1">130.3 (16.9)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">AST (IU/l)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Week 16</td>
                        <td align="char" char="." rowspan="1" colspan="1">41.0 (35.7)</td>
                        <td align="char" char="." rowspan="1" colspan="1">28.2 (16.0)</td>
                        <td align="char" char="." rowspan="1" colspan="1">36.2 (29.1)</td>
                        <td align="char" char="." rowspan="1" colspan="1">27.7 (14.7)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Week 26</td>
                        <td align="char" char="." rowspan="1" colspan="1">38.5 (34.9)</td>
                        <td align="char" char="." rowspan="1" colspan="1">29.6 (26.8)</td>
                        <td align="char" char="." rowspan="1" colspan="1">35.4 (29.8)</td>
                        <td align="char" char="." rowspan="1" colspan="1">29.2 (27.7)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Week 52</td>
                        <td align="char" char="." rowspan="1" colspan="1">40.3 (37.5)</td>
                        <td align="char" char="." rowspan="1" colspan="1">31.2 (29.9)</td>
                        <td align="char" char="." rowspan="1" colspan="1">37.7 (33.8)</td>
                        <td align="char" char="." rowspan="1" colspan="1">30.5 (30.3)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">ALT (IU/l)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Week 16</td>
                        <td align="char" char="." rowspan="1" colspan="1">40.8 (32.6)</td>
                        <td align="char" char="." rowspan="1" colspan="1">30.8 (23.5)</td>
                        <td align="char" char="." rowspan="1" colspan="1">38.0 (28.9)</td>
                        <td align="char" char="." rowspan="1" colspan="1">30.1 (23.1)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Week 26</td>
                        <td align="char" char="." rowspan="1" colspan="1">40.8 (38.9)</td>
                        <td align="char" char="." rowspan="1" colspan="1">30.9 (22.2)</td>
                        <td align="char" char="." rowspan="1" colspan="1">36.7 (31.5)</td>
                        <td align="char" char="." rowspan="1" colspan="1">30.8 (22.9)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Week 52</td>
                        <td align="char" char="." rowspan="1" colspan="1">41.3 (29.7)</td>
                        <td align="char" char="." rowspan="1" colspan="1">33.9 (33.9)</td>
                        <td align="char" char="." rowspan="1" colspan="1">40.4 (30.8)</td>
                        <td align="char" char="." rowspan="1" colspan="1">32.8 (34.3)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">GGT (IU/l)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Week 16</td>
                        <td align="char" char="." rowspan="1" colspan="1">145.1 (467.1)</td>
                        <td align="char" char="." rowspan="1" colspan="1">43.5 (61.9)</td>
                        <td align="char" char="." rowspan="1" colspan="1">87.3 (303.6)</td>
                        <td align="char" char="." rowspan="1" colspan="1">42.9 (63.3)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Week 26</td>
                        <td align="char" char="." rowspan="1" colspan="1">86.6 (223.3)</td>
                        <td align="char" char="." rowspan="1" colspan="1">47.2 (73.2)</td>
                        <td align="char" char="." rowspan="1" colspan="1">73.8 (172.6)</td>
                        <td align="char" char="." rowspan="1" colspan="1">44.9 (72.8)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Week 52</td>
                        <td align="char" char="." rowspan="1" colspan="1">108.6 (245.4)</td>
                        <td align="char" char="." rowspan="1" colspan="1">53.4 (79.4)</td>
                        <td align="char" char="." rowspan="1" colspan="1">29.5 (197.3)</td>
                        <td align="char" char="." rowspan="1" colspan="1">51.2 (75.1)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="acer14018-note-0001">
                      <p>All numbers are observed (percentages are based on valid number of cases) with no imputation for missing data. Biomarker assessments were conducted at the end of treatment (week 16 after baseline) and at 2 assessments after treatment: 10 weeks posttreatment (postbaseline week 26) and 36 weeks posttreatment (postbaseline week 52). ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ‐glutamyltransferase; IU/l, international units per liter; SBP, systolic blood pressure.</p>
                    </fn>
                  </table-wrap-foot>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
                <table-wrap id="acer14018-tbl-0002" xml:lang="en" orientation="portrait" position="float">
                  <label>Table 2</label>
                  <caption>
                    <p>Means (Standard Deviations SDs]) for Each Drinking Outcome by at Least 1‐ and 2‐Level Reductions at Each Assessment Time Point</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1">Outcome</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">No change or increase mean (SD)</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">At least 1‐level reduction mean (SD)</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">1‐level reduction, no change, or increase mean (SD)</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">At least 2‐level reduction mean (SD)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">DrInC</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Week 16</td>
                        <td align="char" char="(" rowspan="1" colspan="1">35.3 (14.3)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">11.0 (16.5)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">24.8 (22.9)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">10.1 (16.1)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Week 26</td>
                        <td align="char" char="(" rowspan="1" colspan="1">37.7 (25.2)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">13.6 (18.1)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">31.6 (24.2)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">11.3 (16.5)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Week 52</td>
                        <td align="char" char="(" rowspan="1" colspan="1">39.9 (23.2)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">16.8 (19.5)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">33.5 (22.8)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">14.8 (18.9)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Week 68</td>
                        <td align="char" char="(" rowspan="1" colspan="1">38.6 (22.9)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">15.7 (20.1)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">33.7 (22.0)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">13.2 (18.3)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">PHDD</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Week 16</td>
                        <td align="char" char="(" rowspan="1" colspan="1">71.3% (32.9%)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">9.1% (17.5%)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">50.7% (38.2%)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">5.9% (11.3%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Week 26</td>
                        <td align="char" char="(" rowspan="1" colspan="1">62.2% (35.4%)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">12.8% (21.9%)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">49.6% (36.6%)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">8.9% (15.6%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Week 52</td>
                        <td align="char" char="(" rowspan="1" colspan="1">67.1% (33.1%)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">15.9% (24.5%)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">55.6% (35.8%)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">10.6% (18.3%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Week 68</td>
                        <td align="char" char="(" rowspan="1" colspan="1">71.4% (32.4%)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">14.9% (23.6%)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">58.9% (35.7%)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">9.5% (16.8%)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">PDD</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Week 16</td>
                        <td align="char" char="(" rowspan="1" colspan="1">77.6% (28.8%)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">18.9% (26.7%)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">59.9% (36.6%)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">15.4% (23.4%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Week 26</td>
                        <td align="char" char="(" rowspan="1" colspan="1">70.5% (32.4%)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">23.9% (29.6%)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">61.2% (34.7%)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">18.2% (25.3%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Week 52</td>
                        <td align="char" char="(" rowspan="1" colspan="1">73.7% (29.8%)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">27.7% (31.9%)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">65.8% (33.4%)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">21.6% (27.8%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Week 68</td>
                        <td align="char" char="(" rowspan="1" colspan="1">78.4% (27.2%)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">27.1% (31.8%)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">69.9% (31.7%)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">20.7% (27.4%)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">DPDD</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Week 16</td>
                        <td align="char" char="(" rowspan="1" colspan="1">12.2 (7.5)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">5.9 (4.1)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">9.9 (6.7)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">5.6 (4.0)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Week 26</td>
                        <td align="char" char="(" rowspan="1" colspan="1">11.8 (7.2)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">4.6 (5.4)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">9.6 (6.6)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">4.1 (5.6)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Week 52</td>
                        <td align="char" char="(" rowspan="1" colspan="1">11.7 (7.1)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">5.7 (6.2)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">9.7 (6.8)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">5.4 (6.4)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Week 68</td>
                        <td align="char" char="(" rowspan="1" colspan="1">11.6 (6.5)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">7.1 (5.7)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">10.1 (6.1)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">6.8 (5.9)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="acer14018-note-0002">
                      <p>All numbers are observed (percentages are based on valid number of cases) with no imputation for missing data. Alcohol consumption and consequences were measured at weeks 16, 26, 52, and 68. DPDD, drinks per drinking day; DrInC, Drinker Inventory of Consequences Total Score; PHDD, percent heavy drinking days; PDD, percent drinking days.</p>
                    </fn>
                  </table-wrap-foot>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
                <table-wrap id="acer14018-tbl-0003" xml:lang="en" orientation="portrait" position="float">
                  <label>Table 3</label>
                  <caption>
                    <p>Linear Mixed Models Results for Functioning Outcomes Over Time Following Treatment as Predicted from 1‐ and 2‐Level Reductions Over Time (<italic>n</italic> = 1,226) and Sensitivity Analyses with Missing = Failure Imputation (<italic>n</italic> = 1,226) and Excluding Abstainers (<italic>n</italic> = 1,052)</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1"/>
                        <th align="center" valign="top" rowspan="1" colspan="1">SBP (mm/Hg)</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">AST (IU/l)</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">ALT (IU/l)</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">GGT (IU/l)</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">DrInC</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">PHDD</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">PDD</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">DPDD</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1"/>
                        <th align="center" valign="top" rowspan="1" colspan="1">B (SE)</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">B (SE)</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">B (SE)</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">B (SE)</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">B (SE)</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">B (SE)</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">B (SE)</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">B (SE)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" colspan="9" rowspan="1">Linear mixed models</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">1‐level reduction</td>
                        <td align="char" char="." rowspan="1" colspan="1">−6.42 (1.11)<xref ref-type="fn" rid="acer14018-note-0004">***</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−7.87 (2.18)<xref ref-type="fn" rid="acer14018-note-0004">***</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−6.33 (2.09)<xref ref-type="fn" rid="acer14018-note-0004">***</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−26.92 (10.47)<xref ref-type="fn" rid="acer14018-note-0004">*</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−19.24 (1.32)<xref ref-type="fn" rid="acer14018-note-0004">***</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−39.89 (1.76)<xref ref-type="fn" rid="acer14018-note-0004">***</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−32.69 (1.62)<xref ref-type="fn" rid="acer14018-note-0004">***</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−4.86 (0.36)<xref ref-type="fn" rid="acer14018-note-0004">***</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">2‐level reduction</td>
                        <td align="char" char="." rowspan="1" colspan="1">−6.00 (0.84)<xref ref-type="fn" rid="acer14018-note-0004">***</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−7.19 (1.55)<xref ref-type="fn" rid="acer14018-note-0004">***</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−6.00 (1.53)<xref ref-type="fn" rid="acer14018-note-0004">***</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−21.84 (7.97)<xref ref-type="fn" rid="acer14018-note-0004">**</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−17.40 (1.08)<xref ref-type="fn" rid="acer14018-note-0004">***</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−38.55 (1.45)<xref ref-type="fn" rid="acer14018-note-0004">***</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−33.65 (1.39)<xref ref-type="fn" rid="acer14018-note-0004">***</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−4.16 (0.28)<xref ref-type="fn" rid="acer14018-note-0004">***</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="9" rowspan="1">Missing = failure models</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">1‐level reduction</td>
                        <td align="char" char="." rowspan="1" colspan="1">−5.69 (1.09)<xref ref-type="fn" rid="acer14018-note-0004">***</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−7.62 (2.09)<xref ref-type="fn" rid="acer14018-note-0004">***</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−6.12 (2.01) <xref ref-type="fn" rid="acer14018-note-0004">**</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−25.60 (10.07)<xref ref-type="fn" rid="acer14018-note-0004">*</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−18.21 (1.27)<xref ref-type="fn" rid="acer14018-note-0004">***</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−29.71 (1.62)<xref ref-type="fn" rid="acer14018-note-0004">***</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−24.53 (1.49)<xref ref-type="fn" rid="acer14018-note-0004">***</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−3.23 (0.31)<xref ref-type="fn" rid="acer14018-note-0004">***</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">2‐level reduction</td>
                        <td align="char" char="." rowspan="1" colspan="1">−5.56 (0.84)<xref ref-type="fn" rid="acer14018-note-0004">***</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−7.13 (1.53)<xref ref-type="fn" rid="acer14018-note-0004">***</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−5.86 (1.50)<xref ref-type="fn" rid="acer14018-note-0004">***</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−21.37 (7.67) <xref ref-type="fn" rid="acer14018-note-0004">**</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−16.84 (1.06)<xref ref-type="fn" rid="acer14018-note-0004">***</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−32.07 (1.41)<xref ref-type="fn" rid="acer14018-note-0004">***</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−28.37 (1.33)<xref ref-type="fn" rid="acer14018-note-0004">***</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−3.25 (0.26)<xref ref-type="fn" rid="acer14018-note-0004">***</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="9" rowspan="1">Excluding abstainers</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">1‐level reduction</td>
                        <td align="char" char="." rowspan="1" colspan="1">−5.14 (1.13)<xref ref-type="fn" rid="acer14018-note-0004">***</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−6.36 (2.15)<xref ref-type="fn" rid="acer14018-note-0004">**</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−4.17 (1.99)<xref ref-type="fn" rid="acer14018-note-0004">*</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−12.64 (6.82)</td>
                        <td align="char" char="." rowspan="1" colspan="1">−14.39 (1.22)<xref ref-type="fn" rid="acer14018-note-0004">***</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−38.27 (1.77)<xref ref-type="fn" rid="acer14018-note-0004">***</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−28.10 (1.63)<xref ref-type="fn" rid="acer14018-note-0004">***</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−3.54 (0.41)<xref ref-type="fn" rid="acer14018-note-0004">***</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">2‐level reduction</td>
                        <td align="char" char="." rowspan="1" colspan="1">−4.26 (0.89)<xref ref-type="fn" rid="acer14018-note-0004">***</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−5.49 (1.60)**</td>
                        <td align="char" char="." rowspan="1" colspan="1">−3.87 (1.56)<xref ref-type="fn" rid="acer14018-note-0004">*</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−8.24 (5.21)</td>
                        <td align="char" char="." rowspan="1" colspan="1">−13.14 (1.02)<xref ref-type="fn" rid="acer14018-note-0004">***</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−38.19 (1.54)<xref ref-type="fn" rid="acer14018-note-0004">***</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−29.34 (1.45)<xref ref-type="fn" rid="acer14018-note-0004">***</xref>
</td>
                        <td align="char" char="." rowspan="1" colspan="1">−2.96 (0.33)<xref ref-type="fn" rid="acer14018-note-0004">***</xref>
</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="acer14018-note-0003">
                      <p>B (SE) = unstandardized regression coefficients (standard error), which can be interpreted as the decrease in outcomes based on achieving at least a 1‐ and 2‐level reduction, at the average of all covariates (covariate effects reported in Table <xref rid="acer14018-sup-0001" ref-type="supplementary-material">S1</xref>); AST, aspartate aminotransferase; ALT, alanine aminotransferase; DPDD, drinks per drinking day; DrInC, Drinker Inventory of Consequences Total Score; GGT, γ‐glutamyltransferase; IU/l, international units per liter; PDD, percent drinking days; PHDD, percent heavy drinking days; SBP, systolic blood pressure. The reference group for the 1‐level reduction was no change or an increase in the WHO risk drinking level from baseline to the treatment/follow‐up months, and the reference group for the 2‐level reduction was the 1‐level reduction, no change, or increase in the WHO risk level from baseline to the treatment/follow‐up months.</p>
                    </fn>
                    <fn id="acer14018-note-0004">
                      <p><italic>*p </italic>&lt;<italic> </italic>0.05, <italic>**p </italic>&lt;<italic> </italic>0.01, <italic>***p </italic>&lt;<italic> </italic>0.001.</p>
                    </fn>
                  </table-wrap-foot>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
              </sec>
              <sec id="acer14018-sec-0020">
                <title>Sensitivity Analyses</title>
                <sec id="acer14018-sec-0021">
                  <title>Imputing Failure for Missing Data</title>
                  <p>All models were re‐estimated with failure imputed for missing data. For the 1‐level reduction outcome, failure was defined as no change or an increase in WHO risk level. For the 2‐level reduction outcome, failure was defined as a 1‐level reduction, no change, or an increase in WHO risk level. The logistic regression models were nearly identical. Achieving at least a 1‐ or 2‐level reduction during the last month of treatment was associated with 9 to 10 times the odds of reporting at least a 1‐ or 2‐level reduction, respectively, at 1 year posttreatment (1‐level reduction: <italic>B</italic>[SE] = 2.33 [0.19], <italic>p </italic>&lt;<italic> </italic>0.001; OR [95% CI] = 10.31 [7.01, 15.16]; 2‐level reduction: <italic>B</italic>[SE] = 2.26 [0.18], <italic>p </italic>&lt;<italic> </italic>0.001; OR [95% CI] = 9.55 [6.77, 13.47]). The results from the linear mixed models were substantively unchanged (see Table <xref rid="acer14018-tbl-0003" ref-type="table">3</xref>).</p>
                </sec>
                <sec id="acer14018-sec-0022">
                  <title>Excluding Abstainers</title>
                  <p>Sensitivity analyses included only individuals who did not achieve abstinence (<italic>n</italic> = 1,052). In this subgroup, the results of the logistic regression models with abstainers excluded were nearly identical to the prior models in which they were included. Achieving at least a 1‐ or 2‐level reduction during the last month of treatment (short of abstinence) was associated with greater than 8 times the odds of reporting at least a 1‐ or 2‐level reduction (short of abstinence), respectively, at 1 year posttreatment (1‐level reduction: <italic>B</italic>[SE] = 2.39 [0.29], <italic>p </italic>&lt;<italic> </italic>0.001; OR [95% CI] = 10.90 [6.14, 19.36]; 2‐level reduction: <italic>B</italic>[SE] = 2.16 [0.26], <italic>p </italic>&lt;<italic> </italic>0.001; OR [95% CI] = 8.69 [5.25, 14.39]). Of those who achieved at least a 1‐level reduction by the end of treatment and were not abstinent, 80.4% reported at least a 1‐level reduction by the 1‐year follow‐up. Similarly, of those who achieved a least a 2‐level reduction by the end of treatment and were not abstinent, 69.5% reported at least a 2‐level reduction at the 1‐year follow‐up. The results from the linear mixed models were similar (see Table <xref rid="acer14018-tbl-0003" ref-type="table">3</xref>), although effects on functional outcomes were smaller with abstainers excluded. In particular, the effects of 1‐ and 2‐level reductions on GGT were not significant with abstainers excluded.</p>
                </sec>
              </sec>
            </sec>
            <sec id="acer14018-sec-0023">
              <title>Discussion</title>
              <p>The current study examined whether 1‐ and 2‐level reductions in WHO risk levels were maintained over time in a large sample of individuals with alcohol dependence who received 4 months of treatment and were followed for 12 months after treatment. Consistent with study hypotheses, the 1‐ and 2‐level reductions were maintained over time and associated with significant improvements in functioning over time up to 1 year posttreatment. Results were robust to sensitivity analyses that imputed failure (e.g., no change or increase in WHO risk level) for missing data. The findings were also consistent when abstainers were excluded from the model, with 1 notable difference: At least 1‐ and 2‐level reductions were not significantly associated with lower GGT.</p>
              <p>The results from the current study are consistent with prior work demonstrating that low‐risk drinking outcomes are maintained up to and beyond 1 year posttreatment (Kline‐Simon et al., <xref rid="acer14018-bib-0016" ref-type="ref">2017</xref>; Maisto et al., <xref rid="acer14018-bib-0020" ref-type="ref">2007</xref>; Witkiewitz et al., <xref rid="acer14018-bib-0039" ref-type="ref">2017b</xref>). The current study makes an important new contribution by specifically focusing on WHO risk level reductions, showing that they are maintained across time and associated with improvements in functional outcomes over time.</p>
              <p>The current study was limited by the data available in the COMBINE study, a clinical trial that did not include measures of all outcomes over time. For example, biomarkers were measured through 9 months following treatment and were thus unavailable at the 1‐year follow‐up. More sensitive biomarkers, such as phosphatidylethanol and ethyl glucuronide, were not available in the COMBINE study data. Percent carbohydrate‐deficient transferrin, a biochemical marker that has previously been associated with the WHO risk level reductions (Witkiewitz et al., <xref rid="acer14018-bib-0037" ref-type="ref">2018</xref>), was not measured at follow‐up months in the COMBINE study. Also, all drinking data were obtained by verbal report. These results were also limited to a 1‐year follow‐up, and there is the possibility that reductions would not be maintained for longer follow‐ups, although there is evidence that reductions in drinking can be sustained over 3‐year and up to 9‐year follow‐ups (Kline‐Simon et al., <xref rid="acer14018-bib-0016" ref-type="ref">2017</xref>; Maisto et al., <xref rid="acer14018-bib-0020" ref-type="ref">2007</xref>). Future studies should extend the current analyses by examining the maintenance of WHO risk level reductions over longer periods of time and with other life functional assessments, such as medical outcomes and costs.</p>
              <p>The current findings build on other recent studies that have provided support for the reduction in WHO risk drinking levels as primary outcomes in clinical trials (Falk et al., <xref rid="acer14018-bib-0009" ref-type="ref">2019</xref>; Hasin et al., <xref rid="acer14018-bib-0013" ref-type="ref">2017</xref>; Knox et al., <xref rid="acer14018-bib-0018" ref-type="ref">2018</xref>, <xref rid="acer14018-bib-0017" ref-type="ref">2019</xref>; Witkiewitz et al., <xref rid="acer14018-bib-0036" ref-type="ref">2017a</xref>, <xref rid="acer14018-bib-0037" ref-type="ref">2018</xref>). We found that 1‐ and 2‐level WHO risk drinking level reductions were maintained across a 1‐year follow‐up for most participants and reductions in WHO risk drinking levels over time corresponded to statistically significant and clinically meaningful differences in blood pressure, liver enzyme levels, alcohol consumption, and drinking‐related consequences, as compared to those among individuals who did not achieve reductions.</p>
              <p>Sensitivity analyses provided further support for the maintenance of drinking reductions, even when abstainers were excluded from the analysis. These findings are particularly important because the majority of individuals with AUD who are seeking treatment prefer nonabstinence goals (DeMartini et al., <xref rid="acer14018-bib-0007" ref-type="ref">2014</xref>; Haug et al., <xref rid="acer14018-bib-0014" ref-type="ref">2018</xref>; Ryan et al., <xref rid="acer14018-bib-0031" ref-type="ref">2017</xref>). Moreover, many people with AUD do not seek treatment because they do not want to completely abstain from alcohol (Park‐Lee et al., <xref rid="acer14018-bib-0029" ref-type="ref">2017</xref>). More individuals with AUD may be interested in seeking treatment if they are aware of the possibility that drinking reduction goals are achievable, sustainable, and associated with improvements in functioning (Mann et al., <xref rid="acer14018-bib-0023" ref-type="ref">2017</xref>; van Amsterdam and van den Brink, <xref rid="acer14018-bib-0034" ref-type="ref">2013</xref>). The expansion of treatment options to be more inclusive of drinking reduction goals is critically important. The current findings show a high probability that such drinking reductions are maintained over time.</p>
            </sec>
            <sec id="acer14018-sec-0025">
              <title>Disclosures</title>
              <p>Dr. Kranzler is named as an inventor on PCT patent application #15/878640 entitled: “Genotype‐guided dosing of opioid agonists,” filed January 24, 2018. Dr. Mann received honoraria for consultancies from Pfizer. Dr. Hasin is Principal Investigator of a study funded by inVentiv Health Consulting that combines support from: Actavis, Inc.; Endo Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Mallinckrodt, LLC; Pfizer, Inc.; Purdue Pharma, L.P.; Rhodes Pharmaceuticals, L.P.; Roxane Laboratories, Inc.; and Zogenix, Inc. Dr. O'Malley reports being a consultant or an advisory board member of Alkermes, Amygdala, Indivior, Mitsubishi Tanabe, and Opiant, and a NIDA Clinical Trials Network DSMB member with honorarium from the Emmes Corporation and donated study medications from Astra Zeneca and Novartis. Dr. Anton has been a consultant in recent past for Insys, Allergan, and Life Epigenetics, has received honorarium from Alkermes for grant reviews, and currently has grant funding from Laboratorio Farmaceutica CT. Drs. Witkiewitz, Kranzler, Mann, Hasin, O'Malley, and Anton are members of the American Society of Clinical Psychopharmacology's Alcohol Clinical Trials Initiative (ACTIVE Group) The ACTIVE Workgroup has been supported previously, but not in the past 36 months, by Abbott/Abbvie, Ethypharm, GSK, Janssen, Lilly, Pfizer, and Schering Plough, but in the past 36 months its activities were supported by Alkermes, Amygdala Neurosciences, Arbor Pharmaceuticals, Indivior, Lundbeck, Mitsubishi, and Otsuka. Drs. Falk and Litten have no disclosures.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material content-type="local-data" id="acer14018-sup-0001">
                <caption>
                  <p><bold>Table S1.</bold> Full results for linear mixed models results for functioning outcomes over time following treatment as predicted from 1‐ and 2‐level reductions over time.</p>
                </caption>
                <media xlink:href="ACER-43-979-s001.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="acer14018-sec-0024">
              <title>Acknowledgments</title>
              <p>This study was funded by the U.S. National Institute on Alcohol Abuse and Alcoholism (R01AA022328). In addition to the authors, the following individuals are or were members of the Alcohol Clinical Trials Initiative (ACTIVE) Workgroup and provided intellectual input during attendance at Workgroup meetings: Joanne Fertig, PhD, and Megan Ryan, PhD, National Institute on Alcohol Abuse and Alcoholism; Tanya Ramey, MD, PhD, and David McCann, PhD, National Institute on Drug Abuse; Didier Meulien, MD, Lundbeck SAS; Anne Andorn, MD, and Jay Graham, MD, Indivior; Roger Meyer, MD, Best Practice Project Management, Inc.; Henri‐Jean Aubin, MD, Paris‐Sud Medical School; Charles O'Brien, MD, PhD, University of Pennsylvania; Bernard Silverman, MD, Alkermes, Inc.; Francoise Trinquet, MD, and Benjamin Zakine, MD, Ethypharm. Lindsay Snyder and Sarah Timm (ASCP) provided important administrative support to the ACTIVE Workgroup.</p>
            </ack>
            <ref-list content-type="cited-references" id="acer14018-bibl-0001">
              <title>References</title>
              <ref id="acer14018-bib-0001">
                <mixed-citation publication-type="book" id="acer14018-cit-0001"><collab collab-type="authors">American Psychiatric Association</collab>
(<year>1994</year>) <chapter-title>Diagnostic and Statistical Manual of Mental Disorders</chapter-title>
<edition>4</edition>th ed. <publisher-name>American Psychiatric Association</publisher-name>, <publisher-loc>Washington, DC</publisher-loc>.</mixed-citation>
              </ref>
              <ref id="acer14018-bib-0002">
                <mixed-citation publication-type="journal" id="acer14018-cit-0002"><string-name><surname>Anton</surname><given-names>RF</given-names></string-name>, <string-name><surname>Litten</surname><given-names>RZ</given-names></string-name>, <string-name><surname>Falk</surname><given-names>DE</given-names></string-name>, <string-name><surname>Palumbo</surname><given-names>JM</given-names></string-name>, <string-name><surname>Bartus</surname><given-names>RT</given-names></string-name>, <string-name><surname>Robinson</surname><given-names>RL</given-names></string-name>, <string-name><surname>Kranzler</surname><given-names>HR</given-names></string-name>, <string-name><surname>Kosten</surname><given-names>TR</given-names></string-name>, <string-name><surname>Meyer</surname><given-names>RE</given-names></string-name>, <string-name><surname>O'Brien</surname><given-names>CP</given-names></string-name>, <string-name><surname>Mann</surname><given-names>K</given-names></string-name>, <string-name><surname>Meulien</surname><given-names>D</given-names></string-name> (<year>2012</year>) <article-title>The Alcohol Clinical Trials Initiative (ACTIVE): purpose and goals for assessing important and salient issues for medications development in alcohol use disorders</article-title>. <source xml:lang="en">Neuropsychopharmacology</source>
<volume>37</volume>:<fpage>402</fpage>–<lpage>411</lpage>.<pub-id pub-id-type="pmid">21900883</pub-id></mixed-citation>
              </ref>
              <ref id="acer14018-bib-0003">
                <mixed-citation publication-type="journal" id="acer14018-cit-0003"><string-name><surname>Anton</surname><given-names>RF</given-names></string-name>, <string-name><surname>O'Malley</surname><given-names>SS</given-names></string-name>, <string-name><surname>Ciraulo</surname><given-names>DA</given-names></string-name>, <string-name><surname>Cisler</surname><given-names>RA</given-names></string-name>, <string-name><surname>Couper</surname><given-names>D</given-names></string-name>, <string-name><surname>Donovan</surname><given-names>DM</given-names></string-name>, <string-name><surname>Gastfriend</surname><given-names>DR</given-names></string-name>, <string-name><surname>Hosking</surname><given-names>JD</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>BA</given-names></string-name>, <string-name><surname>LoCastro</surname><given-names>JS</given-names></string-name>, <string-name><surname>Longabaugh</surname><given-names>R</given-names></string-name>, <string-name><surname>Mason</surname><given-names>BJ</given-names></string-name>, <string-name><surname>Mattson</surname><given-names>ME</given-names></string-name>, <string-name><surname>Miller</surname><given-names>WR</given-names></string-name>, <string-name><surname>Pettinati</surname><given-names>HM</given-names></string-name>, <string-name><surname>Randall</surname><given-names>CL</given-names></string-name>, <string-name><surname>Swift</surname><given-names>R</given-names></string-name>, <string-name><surname>Weiss</surname><given-names>RD</given-names></string-name>, <string-name><surname>Williams</surname><given-names>LD</given-names></string-name>, <string-name><surname>Zweben</surname><given-names>A</given-names></string-name> (<year>2006</year>) <article-title>Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial</article-title>. <source xml:lang="en">J Am Med Assoc</source>
<volume>295</volume>:<fpage>2003</fpage>–<lpage>2017</lpage>.</mixed-citation>
              </ref>
              <ref id="acer14018-bib-0004">
                <mixed-citation publication-type="journal" id="acer14018-cit-0004"><string-name><surname>Aubin</surname><given-names>H‐J</given-names></string-name>, <string-name><surname>Reimer</surname><given-names>J</given-names></string-name>, <string-name><surname>Nutt</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Bladström</surname><given-names>A</given-names></string-name>, <string-name><surname>Torup</surname><given-names>L</given-names></string-name>, <string-name><surname>François</surname><given-names>C</given-names></string-name>, <string-name><surname>Chick</surname><given-names>J</given-names></string-name> (<year>2015</year>) <article-title>Clinical relevance of as‐needed treatment with nalmefene in alcohol‐dependent patients</article-title>. <source xml:lang="en">Eur Addict Res</source>
<volume>21</volume>:<fpage>160</fpage>–<lpage>168</lpage>.<pub-id pub-id-type="pmid">25832297</pub-id></mixed-citation>
              </ref>
              <ref id="acer14018-bib-0005">
                <mixed-citation publication-type="journal" id="acer14018-cit-0005"><collab collab-type="authors">Betty Ford Institute Consensus Panel</collab>
(<year>2007</year>) <article-title>What is recovery? A working definition from the Betty Ford Institute</article-title>. <source xml:lang="en">J Subst Abuse Treat</source>
<volume>33</volume>:<fpage>221</fpage>–<lpage>228</lpage>.<pub-id pub-id-type="pmid">17889294</pub-id></mixed-citation>
              </ref>
              <ref id="acer14018-bib-0006">
                <mixed-citation publication-type="journal" id="acer14018-cit-0006"><string-name><surname>Davis</surname><given-names>AK</given-names></string-name>, <string-name><surname>Rosenberg</surname><given-names>H</given-names></string-name> (<year>2013</year>) <article-title>Acceptance of non‐abstinence goals by addiction professionals in the United States</article-title>. <source xml:lang="en">Psychol Addict Behav</source>
<volume>27</volume>:<fpage>1102</fpage>–<lpage>1109</lpage>.<pub-id pub-id-type="pmid">23088408</pub-id></mixed-citation>
              </ref>
              <ref id="acer14018-bib-0007">
                <mixed-citation publication-type="journal" id="acer14018-cit-0007"><string-name><surname>DeMartini</surname><given-names>KS</given-names></string-name>, <string-name><surname>Devine</surname><given-names>EG</given-names></string-name>, <string-name><surname>DiClemente</surname><given-names>CC</given-names></string-name>, <string-name><surname>Martin</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Ray</surname><given-names>LA</given-names></string-name>, <string-name><surname>O'Malley</surname><given-names>SS</given-names></string-name> (<year>2014</year>) <article-title>Predictors of pretreatment commitment to abstinence: results from the COMBINE study</article-title>. <source xml:lang="en">J Stud Alcohol Drugs</source>
<volume>75</volume>:<fpage>438</fpage>–<lpage>446</lpage>.<pub-id pub-id-type="pmid">24766756</pub-id></mixed-citation>
              </ref>
              <ref id="acer14018-bib-0008">
                <mixed-citation publication-type="book" id="acer14018-cit-0008"><collab collab-type="authors">European Medicines Agency</collab>
(<year>2010</year>) <chapter-title>Guideline on the Development of Medicinal Products for the Treatment of Alcohol Dependence</chapter-title>
<publisher-name>European Medicines Agency</publisher-name>, <publisher-loc>UK</publisher-loc>.</mixed-citation>
              </ref>
              <ref id="acer14018-bib-0009">
                <mixed-citation publication-type="miscellaneous" id="acer14018-cit-0009"><string-name><surname>Falk</surname><given-names>DE</given-names></string-name>, <string-name><surname>O'Malley</surname><given-names>SS</given-names></string-name>, <string-name><surname>Witkiewitz</surname><given-names>K</given-names></string-name>, <string-name><surname>Anton</surname><given-names>RF</given-names></string-name>, <string-name><surname>Litten</surname><given-names>RZ</given-names></string-name>, <string-name><surname>Slater</surname><given-names>M</given-names></string-name>, <string-name><surname>Kranzler</surname><given-names>HR</given-names></string-name>, <string-name><surname>Mann</surname><given-names>KF</given-names></string-name>, <string-name><surname>Hasin</surname><given-names>DS</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>B</given-names></string-name>, <string-name><surname>Meulien</surname><given-names>D</given-names></string-name>, <string-name><surname>Ryan</surname><given-names>M</given-names></string-name>, <string-name><surname>Fertig</surname><given-names>J</given-names></string-name> (<year>2019</year>) <article-title>Evaluation of drinking risk levels as outcomes in alcohol pharmacotherapy trials: a secondary analysis of 3 randomized clinical trials. JAMA Psychiatry</article-title> doi: <pub-id pub-id-type="doi">10.1001/jamapsychiatry.2018.3079</pub-id> [Epub ahead of print].</mixed-citation>
              </ref>
              <ref id="acer14018-bib-0010">
                <mixed-citation publication-type="book" id="acer14018-cit-0010"><collab collab-type="authors">Food and Drug Administration</collab>
(<year>2015</year>) <chapter-title>Alcoholism: Developing Drugs for Treatment</chapter-title> (No. FDA D‐0152‐001). <publisher-name>Center for Drug Evaluation and Research, Food and Drug Administration</publisher-name>, <publisher-loc>Silver Spring, MD</publisher-loc>.</mixed-citation>
              </ref>
              <ref id="acer14018-bib-0011">
                <mixed-citation publication-type="journal" id="acer14018-cit-0011"><string-name><surname>Hallgren</surname><given-names>KA</given-names></string-name>, <string-name><surname>Witkiewitz</surname><given-names>K</given-names></string-name> (<year>2013</year>) <article-title>Missing data in alcohol clinical trials: a comparison of methods</article-title>. <source xml:lang="en">Alcohol Clin Exp Res</source>
<volume>37</volume>:<fpage>2152</fpage>–<lpage>2160</lpage>.<pub-id pub-id-type="pmid">23889334</pub-id></mixed-citation>
              </ref>
              <ref id="acer14018-bib-0012">
                <mixed-citation publication-type="journal" id="acer14018-cit-0012"><string-name><surname>Hallgren</surname><given-names>KA</given-names></string-name>, <string-name><surname>Witkiewitz</surname><given-names>K</given-names></string-name>, <string-name><surname>Kranzler</surname><given-names>HR</given-names></string-name>, <string-name><surname>Falk</surname><given-names>DE</given-names></string-name>, <string-name><surname>Litten</surname><given-names>RZ</given-names></string-name>, <string-name><surname>O'Malley</surname><given-names>SS</given-names></string-name>, <string-name><surname>Anton</surname><given-names>RF</given-names></string-name> (<year>2016</year>) <article-title>Missing data in alcohol clinical trials with binary outcomes</article-title>. <source xml:lang="en">Alcohol Clin Exp Res</source>
<volume>40</volume>:<fpage>1548</fpage>–<lpage>1557</lpage>.<pub-id pub-id-type="pmid">27254113</pub-id></mixed-citation>
              </ref>
              <ref id="acer14018-bib-0013">
                <mixed-citation publication-type="journal" id="acer14018-cit-0013"><string-name><surname>Hasin</surname><given-names>DS</given-names></string-name>, <string-name><surname>Wall</surname><given-names>M</given-names></string-name>, <string-name><surname>Witkiewitz</surname><given-names>K</given-names></string-name>, <string-name><surname>Kranzler</surname><given-names>HR</given-names></string-name>, <string-name><surname>Falk</surname><given-names>D</given-names></string-name>, <string-name><surname>Litten</surname><given-names>R</given-names></string-name>, <string-name><surname>Mann</surname><given-names>K</given-names></string-name>, <string-name><surname>O'Malley</surname><given-names>SS</given-names></string-name>, <string-name><surname>Scodes</surname><given-names>J</given-names></string-name>, <string-name><surname>Robinson</surname><given-names>RL</given-names></string-name>, <string-name><surname>Anton</surname><given-names>R</given-names></string-name>, <string-name><surname>Fertig</surname><given-names>J</given-names></string-name>, <string-name><surname>Isenberg</surname><given-names>K</given-names></string-name>, <string-name><surname>McCann</surname><given-names>D</given-names></string-name>, <string-name><surname>Meulien</surname><given-names>D</given-names></string-name>, <string-name><surname>Meyer</surname><given-names>R</given-names></string-name>, <string-name><surname>O'Brien</surname><given-names>C</given-names></string-name>, <string-name><surname>Ryan</surname><given-names>M</given-names></string-name>, <string-name><surname>Silverman</surname><given-names>B</given-names></string-name>, <string-name><surname>Trinquet</surname><given-names>F</given-names></string-name>, <string-name><surname>Wong</surname><given-names>C</given-names></string-name>, <string-name><surname>Zakine</surname><given-names>B</given-names></string-name> (<year>2017</year>) <article-title>Change in non‐abstinent WHO drinking risk levels and alcohol dependence: a 3 year follow‐up study in the US general population</article-title>. <source xml:lang="en">Lancet Psychiatry</source>
<volume>4</volume>:<fpage>469</fpage>–<lpage>476</lpage>.<pub-id pub-id-type="pmid">28456501</pub-id></mixed-citation>
              </ref>
              <ref id="acer14018-bib-0014">
                <mixed-citation publication-type="journal" id="acer14018-cit-0014"><string-name><surname>Haug</surname><given-names>S</given-names></string-name>, <string-name><surname>Castro</surname><given-names>RP</given-names></string-name>, <string-name><surname>Eggli</surname><given-names>P</given-names></string-name>, <string-name><surname>Schaub</surname><given-names>MP</given-names></string-name> (<year>2018</year>) <article-title>Drinking goal trajectories and their association with client characteristics and outcomes among clients in outpatient alcohol treatment</article-title>. <source xml:lang="en">Subst Use Misuse</source>
<volume>53</volume>:<fpage>2140</fpage>–<lpage>2151</lpage>.<pub-id pub-id-type="pmid">29652560</pub-id></mixed-citation>
              </ref>
              <ref id="acer14018-bib-0015">
                <mixed-citation publication-type="journal" id="acer14018-cit-0015"><string-name><surname>Hunt</surname><given-names>WA</given-names></string-name>, <string-name><surname>Barnett</surname><given-names>LW</given-names></string-name>, <string-name><surname>Branch</surname><given-names>LG</given-names></string-name> (<year>1971</year>) <article-title>Relapse rates in addiction programs</article-title>. <source xml:lang="en">J Clin Psychol</source>
<volume>27</volume>:<fpage>455</fpage>–<lpage>456</lpage>.<pub-id pub-id-type="pmid">5115648</pub-id></mixed-citation>
              </ref>
              <ref id="acer14018-bib-0016">
                <mixed-citation publication-type="journal" id="acer14018-cit-0016"><string-name><surname>Kline‐Simon</surname><given-names>AH</given-names></string-name>, <string-name><surname>Litten</surname><given-names>RZ</given-names></string-name>, <string-name><surname>Weisner</surname><given-names>CM</given-names></string-name>, <string-name><surname>Falk</surname><given-names>DE</given-names></string-name> (<year>2017</year>) <article-title>Posttreatment low‐risk drinking as a predictor of future drinking and problem outcomes among individuals with alcohol use disorders: a 9‐year follow‐up</article-title>. <source xml:lang="en">Alcohol Clin Exp Res</source>
<volume>41</volume>:<fpage>653</fpage>–<lpage>658</lpage>.<pub-id pub-id-type="pmid">28072453</pub-id></mixed-citation>
              </ref>
              <ref id="acer14018-bib-0017">
                <mixed-citation publication-type="journal" id="acer14018-cit-0017"><string-name><surname>Knox</surname><given-names>J</given-names></string-name>, <string-name><surname>Scodes</surname><given-names>J</given-names></string-name>, <string-name><surname>Wall</surname><given-names>M</given-names></string-name>, <string-name><surname>Witkiewitz</surname><given-names>K</given-names></string-name>, <string-name><surname>Kranzler</surname><given-names>HR</given-names></string-name>, <string-name><surname>Falk</surname><given-names>D</given-names></string-name>, <string-name><surname>Litten</surname><given-names>R</given-names></string-name>, <string-name><surname>Mann</surname><given-names>K</given-names></string-name>, <string-name><surname>O'Malley</surname><given-names>SS</given-names></string-name>, <string-name><surname>Anton</surname><given-names>R</given-names></string-name>, <string-name><surname>Hasin</surname><given-names>DS</given-names></string-name> (<year>2019</year>) <article-title>Reduction in non‐abstinent WHO drinking risk levels and depression/anxiety disorders: 3‐year follow‐up results in the US general population</article-title>. <source xml:lang="en">Drug Alcohol Depend</source>
<volume>197</volume>:<fpage>228</fpage>–<lpage>235</lpage>.<pub-id pub-id-type="pmid">30852375</pub-id></mixed-citation>
              </ref>
              <ref id="acer14018-bib-0018">
                <mixed-citation publication-type="journal" id="acer14018-cit-0018"><string-name><surname>Knox</surname><given-names>J</given-names></string-name>, <string-name><surname>Wall</surname><given-names>M</given-names></string-name>, <string-name><surname>Witkiewitz</surname><given-names>K</given-names></string-name>, <string-name><surname>Kranzler</surname><given-names>HR</given-names></string-name>, <string-name><surname>Falk</surname><given-names>D</given-names></string-name>, <string-name><surname>Litten</surname><given-names>R</given-names></string-name>, <string-name><surname>Mann</surname><given-names>K</given-names></string-name>, <string-name><surname>O'Malley</surname><given-names>SS</given-names></string-name>, <string-name><surname>Scodes</surname><given-names>J</given-names></string-name>, <string-name><surname>Anton</surname><given-names>R</given-names></string-name>, <string-name><surname>Hasin</surname><given-names>DS</given-names></string-name>; <collab collab-type="authors">Alcohol Clinical Trials (ACTIVE) Workgroup</collab>
(<year>2018</year>) <article-title>Reduction in nonabstinent WHO drinking risk levels and change in risk for liver disease and positive AUDIT‐C scores: prospective 3‐year follow‐up results in the U.S. general population</article-title>. <source xml:lang="en">Alcohol Clin Exp Res</source>
<volume>42</volume>:<fpage>2256</fpage>–<lpage>2265</lpage>.<pub-id pub-id-type="pmid">30204248</pub-id></mixed-citation>
              </ref>
              <ref id="acer14018-bib-0019">
                <mixed-citation publication-type="journal" id="acer14018-cit-0019"><string-name><surname>Kwo</surname><given-names>PY</given-names></string-name>, <string-name><surname>Cohen</surname><given-names>SM</given-names></string-name>, <string-name><surname>Lim</surname><given-names>JK</given-names></string-name> (<year>2017</year>) <article-title>ACG clinical guideline: evaluation of abnormal liver chemistries</article-title>. <source xml:lang="en">Am J Gastroenterol</source>
<volume>112</volume>:<fpage>18</fpage>–<lpage>35</lpage>.<pub-id pub-id-type="pmid">27995906</pub-id></mixed-citation>
              </ref>
              <ref id="acer14018-bib-0020">
                <mixed-citation publication-type="journal" id="acer14018-cit-0020"><string-name><surname>Maisto</surname><given-names>SA</given-names></string-name>, <string-name><surname>Clifford</surname><given-names>PR</given-names></string-name>, <string-name><surname>Stout</surname><given-names>RL</given-names></string-name>, <string-name><surname>Davis</surname><given-names>CM</given-names></string-name> (<year>2007</year>) <article-title>Moderate drinking in the first year after treatment as a predictor of three‐year outcomes</article-title>. <source xml:lang="en">J Stud Alcohol Drugs</source>
<volume>68</volume>:<fpage>419</fpage>–<lpage>427</lpage>.<pub-id pub-id-type="pmid">17446982</pub-id></mixed-citation>
              </ref>
              <ref id="acer14018-bib-0021">
                <mixed-citation publication-type="journal" id="acer14018-cit-0021"><string-name><surname>Maisto</surname><given-names>SA</given-names></string-name>, <string-name><surname>Hallgren</surname><given-names>KA</given-names></string-name>, <string-name><surname>Roos</surname><given-names>CR</given-names></string-name>, <string-name><surname>Witkiewitz</surname><given-names>K</given-names></string-name> (<year>2018</year>) <article-title>Course of remission from and relapse to heavy drinking following outpatient treatment of alcohol use disorder</article-title>. <source xml:lang="en">Drug Alcohol Depend</source>
<volume>187</volume>:<fpage>319</fpage>–<lpage>326</lpage>.<pub-id pub-id-type="pmid">29705545</pub-id></mixed-citation>
              </ref>
              <ref id="acer14018-bib-0022">
                <mixed-citation publication-type="journal" id="acer14018-cit-0022"><string-name><surname>Maisto</surname><given-names>SA</given-names></string-name>, <string-name><surname>Witkiewitz</surname><given-names>K</given-names></string-name>, <string-name><surname>Moskal</surname><given-names>D</given-names></string-name>, <string-name><surname>Wilson</surname><given-names>AD</given-names></string-name> (<year>2016</year>) <article-title>Is the construct of relapse heuristic, and does it advance alcohol use disorder clinical practice?</article-title>
<source xml:lang="en">J Stud Alcohol Drugs</source>
<volume>77</volume>:<fpage>849</fpage>–<lpage>858</lpage>.<pub-id pub-id-type="pmid">27797685</pub-id></mixed-citation>
              </ref>
              <ref id="acer14018-bib-0023">
                <mixed-citation publication-type="journal" id="acer14018-cit-0023"><string-name><surname>Mann</surname><given-names>K</given-names></string-name>, <string-name><surname>Aubin</surname><given-names>H‐J</given-names></string-name>, <string-name><surname>Witkiewitz</surname><given-names>K</given-names></string-name> (<year>2017</year>) <article-title>Reduced drinking in alcohol dependence treatment, what is the evidence?</article-title>
<source xml:lang="en">Eur Addict Res</source>
<volume>23</volume>:<fpage>219</fpage>–<lpage>230</lpage>.<pub-id pub-id-type="pmid">28934736</pub-id></mixed-citation>
              </ref>
              <ref id="acer14018-bib-0024">
                <mixed-citation publication-type="book" id="acer14018-cit-0024"><string-name><surname>Miller</surname><given-names>WR</given-names></string-name> (<year>1996</year>) <chapter-title>Form 90: A Structured Assessment Interview for Drinking and Related Behaviors</chapter-title>, Project MA. ed. <publisher-name>National Institute on Alcohol Abuse and Alcoholism</publisher-name>, <publisher-loc>Bethesda, MD</publisher-loc>.</mixed-citation>
              </ref>
              <ref id="acer14018-bib-0025">
                <mixed-citation publication-type="book" id="acer14018-cit-0025"><string-name><surname>Miller</surname><given-names>WR</given-names></string-name>, <string-name><surname>Tonigan</surname><given-names>JS</given-names></string-name>, <string-name><surname>Longabaugh</surname><given-names>R</given-names></string-name> (<year>1995</year>) <chapter-title>The Drinker Inventory of Consequences (DrInC)</chapter-title>, Project MA, ed. <publisher-name>National Institute on Alcohol Abuse and Alcoholism</publisher-name>, <publisher-loc>Bethesda, MD</publisher-loc>.</mixed-citation>
              </ref>
              <ref id="acer14018-bib-0026">
                <mixed-citation publication-type="miscellaneous" id="acer14018-cit-0026"><string-name><surname>Muthén</surname><given-names>LK</given-names></string-name>, <string-name><surname>Muthén</surname><given-names>BO</given-names></string-name> (<year>1998</year>‐2017) <article-title>Mplus User's Guide. 8th ed. Muthén &amp; Muthén, Los Angeles, CA</article-title>.</mixed-citation>
              </ref>
              <ref id="acer14018-bib-0027">
                <mixed-citation publication-type="book" id="acer14018-cit-0027"><collab collab-type="authors">National Institute on Alcohol Abuse and Alcoholism</collab>
(<year>2005</year>) <chapter-title>Helping Patients Who Drink Too Much: A Clinician's Guide</chapter-title>
<publisher-name>National Institutes of Health</publisher-name>, <publisher-loc>Bethesda, MD</publisher-loc>.</mixed-citation>
              </ref>
              <ref id="acer14018-bib-0028">
                <mixed-citation publication-type="journal" id="acer14018-cit-0028"><string-name><surname>O'Malley</surname><given-names>SS</given-names></string-name>, <string-name><surname>Todtenkopf</surname><given-names>MS</given-names></string-name>, <string-name><surname>Du</surname><given-names>Y</given-names></string-name>, <string-name><surname>Ehrich</surname><given-names>E</given-names></string-name>, <string-name><surname>Silverman</surname><given-names>BL</given-names></string-name> (<year>2018</year>) <article-title>Effects of the opioid system modulator, samidorphan, on measures of alcohol consumption and patient‐reported outcomes in adults with alcohol dependence</article-title>. <source xml:lang="en">Alcohol Clin Exp Res</source>
<volume>42</volume>:<fpage>2011</fpage>–<lpage>2021</lpage>.<pub-id pub-id-type="pmid">30055046</pub-id></mixed-citation>
              </ref>
              <ref id="acer14018-bib-0029">
                <mixed-citation publication-type="miscellaneous" id="acer14018-cit-0029"><string-name><surname>Park‐Lee</surname><given-names>E</given-names></string-name>, <string-name><surname>Lipari</surname><given-names>RN</given-names></string-name>, <string-name><surname>Hedden</surname><given-names>SL</given-names></string-name>, <string-name><surname>Kroutil</surname><given-names>LA</given-names></string-name>, <string-name><surname>Porter</surname><given-names>JD</given-names></string-name> (<year>2017</year>) <article-title>Receipt of services for substance use and mental health issues among adults: results from the 2016 National Survey on Drug Use and Health</article-title>. Available at: <ext-link ext-link-type="uri" xlink:href="https://www.samhsa.gov/data/sites/default/files/NSDUH-DR-FFR2-2016/NSDUH-DR-FFR2-2016.htm#topofpage">https://www.samhsa.gov/data/sites/default/files/NSDUH-DR-FFR2-2016/NSDUH-DR-FFR2-2016.htm#topofpage</ext-link>. Accessed March 22, 2019.</mixed-citation>
              </ref>
              <ref id="acer14018-bib-0030">
                <mixed-citation publication-type="journal" id="acer14018-cit-0030"><string-name><surname>Rosenberg</surname><given-names>H</given-names></string-name>, <string-name><surname>Davis</surname><given-names>LA</given-names></string-name> (<year>1994</year>) <article-title>Acceptance of moderate drinking by alcohol treatment services in the United States</article-title>. <source xml:lang="en">J Stud Alcohol</source>
<volume>55</volume>:<fpage>167</fpage>–<lpage>172</lpage>.<pub-id pub-id-type="pmid">8189737</pub-id></mixed-citation>
              </ref>
              <ref id="acer14018-bib-0031">
                <mixed-citation publication-type="journal" id="acer14018-cit-0031"><string-name><surname>Ryan</surname><given-names>ML</given-names></string-name>, <string-name><surname>Falk</surname><given-names>DE</given-names></string-name>, <string-name><surname>Fertig</surname><given-names>JB</given-names></string-name>, <string-name><surname>Rendenbach‐Mueller</surname><given-names>B</given-names></string-name>, <string-name><surname>Katz</surname><given-names>DA</given-names></string-name>, <string-name><surname>Tracy</surname><given-names>KA</given-names></string-name>, <string-name><surname>Strain</surname><given-names>EC</given-names></string-name>, <string-name><surname>Dunn</surname><given-names>KE</given-names></string-name>, <string-name><surname>Kampman</surname><given-names>K</given-names></string-name>, <string-name><surname>Mahoney</surname><given-names>E</given-names></string-name>, <string-name><surname>Ciraulo</surname><given-names>DA</given-names></string-name>, <string-name><surname>Sickles‐Colaneri</surname><given-names>L</given-names></string-name>, <string-name><surname>Ait‐Daoud</surname><given-names>N</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>BA</given-names></string-name>, <string-name><surname>Ransom</surname><given-names>J</given-names></string-name>, <string-name><surname>Scott</surname><given-names>C</given-names></string-name>, <string-name><surname>Koob</surname><given-names>GF</given-names></string-name>, <string-name><surname>Litten</surname><given-names>RZ</given-names></string-name> (<year>2017</year>) <article-title>A phase 2, double‐blind, placebo‐controlled randomized trial assessing the efficacy of ABT‐436, a novel v1b receptor antagonist, for alcohol dependence</article-title>. <source xml:lang="en">Neuropsychopharmacology</source>
<volume>42</volume>:<fpage>1012</fpage>–<lpage>1023</lpage>.<pub-id pub-id-type="pmid">27658483</pub-id></mixed-citation>
              </ref>
              <ref id="acer14018-bib-0032">
                <mixed-citation publication-type="book" id="acer14018-cit-0032"><string-name><surname>Sobell</surname><given-names>LC</given-names></string-name>, <string-name><surname>Sobell</surname><given-names>MB</given-names></string-name> (<year>1992</year>) <chapter-title>back: a technique for assessing self‐reported alcohol consumption</chapter-title>, in <source xml:lang="en">Measuring Alcohol Consumption: Psychosocial and Biological Methods</source> (<person-group person-group-type="editor"><name><surname>Litten</surname><given-names>RZ</given-names></name></person-group>, <person-group person-group-type="editor"><name><surname>Allenl</surname><given-names>JP</given-names></name></person-group> eds), pp <fpage>41</fpage>–<lpage>72</lpage>. <publisher-name>Humana Press</publisher-name>, <publisher-loc>Totowa, NJ</publisher-loc>.</mixed-citation>
              </ref>
              <ref id="acer14018-bib-0033">
                <mixed-citation publication-type="journal" id="acer14018-cit-0033"><string-name><surname>Strandberg</surname><given-names>T</given-names></string-name>, <string-name><surname>Pitkala</surname><given-names>K</given-names></string-name> (<year>2003</year>) <article-title>What is the most important component of blood pressure: systolic, diastolic or pulse pressure?</article-title>
<source xml:lang="en">Curr Opin Nephrol Hypertens</source>
<volume>12</volume>:<fpage>293</fpage>–<lpage>297</lpage>.<pub-id pub-id-type="pmid">12698068</pub-id></mixed-citation>
              </ref>
              <ref id="acer14018-bib-0034">
                <mixed-citation publication-type="journal" id="acer14018-cit-0034"><string-name><surname>van Amsterdam</surname><given-names>J</given-names></string-name>, <string-name><surname>van den Brink</surname><given-names>W</given-names></string-name> (<year>2013</year>) <article-title>Reduced‐risk drinking as a viable treatment goal in problematic alcohol use and alcohol dependence</article-title>. <source xml:lang="en">J Psychopharmacol</source>
<volume>27</volume>:<fpage>987</fpage>–<lpage>997</lpage>.<pub-id pub-id-type="pmid">23824247</pub-id></mixed-citation>
              </ref>
              <ref id="acer14018-bib-0035">
                <mixed-citation publication-type="journal" id="acer14018-cit-0035"><string-name><surname>Witkiewitz</surname><given-names>K</given-names></string-name>, <string-name><surname>Falk</surname><given-names>DE</given-names></string-name>, <string-name><surname>Kranzler</surname><given-names>HR</given-names></string-name>, <string-name><surname>Litten</surname><given-names>RZ</given-names></string-name>, <string-name><surname>Hallgren</surname><given-names>KA</given-names></string-name>, <string-name><surname>O'Malley</surname><given-names>SS</given-names></string-name>, <string-name><surname>Anton</surname><given-names>RF</given-names></string-name> (<year>2014</year>) <article-title>Methods to analyze treatment effects in the presence of missing data for a continuous heavy drinking outcome measure when participants drop out from treatment in alcohol clinical trials</article-title>. <source xml:lang="en">Alcohol Clin Exp Res</source>
<volume>38</volume>:<fpage>2826</fpage>–<lpage>2834</lpage>.<pub-id pub-id-type="pmid">25421518</pub-id></mixed-citation>
              </ref>
              <ref id="acer14018-bib-0036">
                <mixed-citation publication-type="journal" id="acer14018-cit-0036"><string-name><surname>Witkiewitz</surname><given-names>K</given-names></string-name>, <string-name><surname>Hallgren</surname><given-names>KA</given-names></string-name>, <string-name><surname>Kranzler</surname><given-names>HR</given-names></string-name>, <string-name><surname>Mann</surname><given-names>KF</given-names></string-name>, <string-name><surname>Hasin</surname><given-names>DS</given-names></string-name>, <string-name><surname>Falk</surname><given-names>DE</given-names></string-name>, <string-name><surname>Litten</surname><given-names>RZ</given-names></string-name>, <string-name><surname>O'Malley</surname><given-names>SS</given-names></string-name>, <string-name><surname>Anton</surname><given-names>RF</given-names></string-name> (<year>2017a</year>) <article-title>Clinical validation of reduced alcohol consumption after treatment for alcohol dependence using the World Health Organization risk drinking levels</article-title>. <source xml:lang="en">Alcohol Clin Exp Res</source>
<volume>41</volume>:<fpage>179</fpage>–<lpage>186</lpage>.<pub-id pub-id-type="pmid">28019652</pub-id></mixed-citation>
              </ref>
              <ref id="acer14018-bib-0037">
                <mixed-citation publication-type="journal" id="acer14018-cit-0037"><string-name><surname>Witkiewitz</surname><given-names>K</given-names></string-name>, <string-name><surname>Kranzler</surname><given-names>HR</given-names></string-name>, <string-name><surname>Hallgren</surname><given-names>KA</given-names></string-name>, <string-name><surname>O'Malley</surname><given-names>SS</given-names></string-name>, <string-name><surname>Falk</surname><given-names>DE</given-names></string-name>, <string-name><surname>Litten</surname><given-names>RZ</given-names></string-name>, <string-name><surname>Hasin</surname><given-names>DS</given-names></string-name>, <string-name><surname>Mann</surname><given-names>KF</given-names></string-name>, <string-name><surname>Anton</surname><given-names>RF</given-names></string-name> (<year>2018</year>) <article-title>Drinking risk level reductions associated with improvements in physical health and quality of life among individuals with alcohol use disorder</article-title>. <source xml:lang="en">Alcohol Clin Exp Res</source>
<volume>42</volume>:<fpage>2453</fpage>–<lpage>2465</lpage>.<pub-id pub-id-type="pmid">30395350</pub-id></mixed-citation>
              </ref>
              <ref id="acer14018-bib-0038">
                <mixed-citation publication-type="journal" id="acer14018-cit-0038"><string-name><surname>Witkiewitz</surname><given-names>K</given-names></string-name>, <string-name><surname>Masyn</surname><given-names>KE</given-names></string-name> (<year>2008</year>) <article-title>Drinking trajectories following an initial lapse</article-title>. <source xml:lang="en">Psychol Addict Behav</source>
<volume>22</volume>:<fpage>157</fpage>–<lpage>167</lpage>.<pub-id pub-id-type="pmid">18540713</pub-id></mixed-citation>
              </ref>
              <ref id="acer14018-bib-0039">
                <mixed-citation publication-type="journal" id="acer14018-cit-0039"><string-name><surname>Witkiewitz</surname><given-names>K</given-names></string-name>, <string-name><surname>Wilson</surname><given-names>AD</given-names></string-name>, <string-name><surname>Pearson</surname><given-names>MR</given-names></string-name>, <string-name><surname>Hallgren</surname><given-names>KA</given-names></string-name>, <string-name><surname>Falk</surname><given-names>DE</given-names></string-name>, <string-name><surname>Litten</surname><given-names>RZ</given-names></string-name>, <string-name><surname>Kranzler</surname><given-names>HR</given-names></string-name>, <string-name><surname>Mann</surname><given-names>KF</given-names></string-name>, <string-name><surname>Hasin</surname><given-names>DS</given-names></string-name>, <string-name><surname>O'Malley</surname><given-names>SS</given-names></string-name>, <string-name><surname>Anton</surname><given-names>RF</given-names></string-name> (<year>2017b</year>) <article-title>Temporal stability of heavy drinking days and drinking reductions among heavy drinkers in the COMBINE study</article-title>. <source xml:lang="en">Alcohol Clin Exp Res</source>
<volume>41</volume>:<fpage>1054</fpage>–<lpage>1062</lpage>.<pub-id pub-id-type="pmid">28295414</pub-id></mixed-citation>
              </ref>
              <ref id="acer14018-bib-0040">
                <mixed-citation publication-type="book" id="acer14018-cit-0040"><collab collab-type="authors">World Health Organization (WHO)</collab>
(<year>2000</year>) <chapter-title>International Guide for Monitoring Alcohol Consumption and Related Harm</chapter-title>
<publisher-name>World Health Organization</publisher-name>, <publisher-loc>Geneva, Switzerland</publisher-loc>.</mixed-citation>
              </ref>
              <ref id="acer14018-bib-0041">
                <mixed-citation publication-type="journal" id="acer14018-cit-0041"><string-name><surname>Yuan</surname><given-names>K‐H</given-names></string-name>, <string-name><surname>Bentler</surname><given-names>PM</given-names></string-name> (<year>2010</year>) <article-title>Finite normal mixture SEM analysis by fitting multiple conventional SEM models</article-title>. <source xml:lang="en">Sociol Methodol</source>
<volume>40</volume>:<fpage>191</fpage>–<lpage>245</lpage>.<pub-id pub-id-type="pmid">21170153</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
